US-based digital health solutions provider Aptar Digital Health has partnered with SHL Medical, a provider of advanced drug delivery systems, to extend SHL’s connected device technologies.

The collaboration will use Aptar Digital Health’s Software as a Medical Device (SaMD) platform to provide digital solutions that help patients on injectable therapies manage their disease.

SHL Medical’s medical devices, such as the Molly Connected Cap, will benefit from Aptar Digital Health’s SaMD platform to enhance the patient experience.

Molly Connected Cap is a smart retrofittable add-on for SHL Medical’s Molly modular platform autoinjector and offers additional support during self-administration via a digital solution.

SHL Medical chief technical officer Ralph Howald: “The increasing need for home-based treatments and the evolving healthcare landscape have created a need for collaborative innovation within the drug delivery industry.

“With our combined expertise, the partnership with Aptar Digital Health will serve as the first step in realizing a thoroughly-needed digital ecosystem for injectable drugs, starting with a digital transformation that will impact the end-to-end value chain in the future.”

Aptar’s SaMD platform will provide digital health solutions adapted to the patient’s profile, disease state and treatment plan to empower them during their treatment journey.

Under the partnership, SHL Medical will recommend Aptar Digital Health as a trusted digital partner.

Aptar Digital Health has a large portfolio of regulated digital health solutions and connected devices across multiple therapeutic areas and modes of administration.

The collaboration will combine the capabilities of both companies to develop end-to-end solutions to support the enhancement of the patient experience during self-injection.

Through the partnership, Aptar Digital Health aims to strengthen its portfolio of digital products and services to enhance the patient experience across the treatment journey.

Aptar Digital Health president Sai Shankar said: “Embarking on a self-injection therapy and adhering to a consistent injection schedule can pose a challenge to patients in being actively involved in their treatment journey.

“By joining forces with SHL Medical, a world-class leader in innovative drug delivery systems, we aim to positively and durably change the experience of patients who must self-inject regularly.”